Heinz-Josef Lenz, MD, FACP, University of Southern California, Los Angeles, CA, provides an update on the use of nivolumab and ipilimumab as first-line therapy in patients with microsatellite instability-high or mismatch repair-deficient (MSI-H/dMMR) colorectal cancer (CRC), as evaluated in two recently published studies, KEYNOTE-177 (NCT02563002) and CheckMate 142 (NCT02060188). Prof. Lenz also explores the role of KRAS signaling in mediating an immune response associated with checkpoint blockade. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
